---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112405"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:02:25.908356+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fennec Pharma appoints new CMO, CCO, CSO to accelerate growth

## Summary
- Pierre Sayad appointed CMO, Terry Evans CCO, Christiana Cioffi CSO, effective Oct. 28, 2024.
- Sayad receives $450,000 base salary and 150,000 options; Evans $400,000 + 150,000 options.
- Cioffi receives $375,000 base salary and 150,000 options; each eligible for 40% target bonus.
- All three executives have extensive oncology and rare disease launch experience.
- Appointments aim to boost commercialization of PEDMARK for cisplatin-induced ototoxicity.

## SEC filing metadata
- accession: 0001104659-24-112405
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/tm2427086d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112405
- JSON: https://secwatch.observer/filing/0001104659-24-112405.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112405.txt

## Key facts
- Executive change
  Christiana Cioffi was appointed as Chief Strategy Officer at FENNEC PHARMACEUTICALS INC..
  - Action: appointed
  - Role: Chief Strategy Officer
  source text: Ms. Christiana Cioffi, MBA, as Chief Strategy Officer ("CSO"),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm
- Executive change
  Pierre S. Sayad was appointed as Chief Medical Officer at FENNEC PHARMACEUTICALS INC..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On October 28, 2024, Fennec Pharmaceuticals Inc.'s (the "Company") announced the appointments of Mr. Pierre S. Sayad, PhD, M.S., as Chief Medical Officer ("CMO"),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm
- Executive change
  Terry Evans was appointed as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: Mr. Terry Evans as Chief Commercial Officer ("CCO"),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.